Journey Medical Corporation — Third Quarter 2026 Earnings Summary

Journey Medical Corporation reported total revenues of $19.0 million for the third quarter of 2026, representing an 8% increase from the prior year period. The company's flagship product, Emrosi, generated $9.0 million in revenue, marking an 84% year-over-year growth driven by increased prescription demand and improved reimbursement mixes. Gross margin improved to 69% for the quarter, while the GAAP net loss narrowed to $1.3 million compared to $2.3 million in the same period of 2025. The company ended the quarter with $22.3 million in cash and cash equivalents and achieved positive non-GAAP EBITDA of $3.5 million.